Human Tuberculosis Vaccine Market, By Type (Live attenuated vaccine, Inactivated, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Private and Public), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Nov 2024

Code : CMI5209

Pages :197

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

On May 8, 2024, Bharat Biotech, a biotechnology company, announced that the Central Drug Standard Control Organisation (CDSCO) approved its proposal to conduct Phase II clinical trials for the Mycobacterium Tuberculosis (Live Attenuated) Vaccine, known as MTBVAC. The Phase II clinical trials aim to assess the safety and immunogenicity of MTBVAC in healthy adolescent and adult populations.
On March 24, 2024, Bharat Biotech announced the start of clinical trials for its tuberculosis vaccine, MTBVAC, on adults in India. MTBVAC is a live attenuated vaccine derived from a human strain of Mycobacterium tuberculosis. Unlike the traditional BCG vaccine, MTBVAC includes all antigens found in strains that infect humans, potentially providing broader protection against tuberculosis
In May 2023, Biofabri, a subsidiary of Zendal, and IAVI, an international nonprofit focused on vaccine and antibody development, announced a partnership for the comprehensive development of the tuberculosis vaccine candidate MTBVAC. Under this agreement, IAVI will assist with development, global regulatory strategies, resource mobilization, and access planning for the MTBVAC program targeting adolescents and adults.
In January 2023, the World Health Organization (WHO) announced the creation of a Tuberculosis Vaccine Accelerator Council. This initiative aims to accelerate the development and deployment of effective tuberculosis vaccines by addressing barriers and fostering collaboration among stakeholders in the global health community.